These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34667954)

  • 21. The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review.
    Abufaraj M; Dalbagni G; Daneshmand S; Horenblas S; Kamat AM; Kanzaki R; Zlotta AR; Shariat SF
    Eur Urol; 2018 Apr; 73(4):543-557. PubMed ID: 29122377
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of Radical Cystectomy in Non-Organ Confined Bladder Cancer: A Systematic Review.
    Li R; Metcalfe M; Kukreja J; Navai N
    Bladder Cancer; 2018 Jan; 4(1):31-40. PubMed ID: 29430505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature.
    Soukup V; Babjuk M; Bellmunt J; Dalbagni G; Giannarini G; Hakenberg OW; Herr H; Lechevallier E; Ribal MJ
    Eur Urol; 2012 Aug; 62(2):290-302. PubMed ID: 22609313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density.
    Stein JP; Cai J; Groshen S; Skinner DG
    J Urol; 2003 Jul; 170(1):35-41. PubMed ID: 12796639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
    Cambier S; Sylvester RJ; Collette L; Gontero P; Brausi MA; van Andel G; Kirkels WJ; Silva FC; Oosterlinck W; Prescott S; Kirkali Z; Powell PH; de Reijke TM; Turkeri L; Collette S; Oddens J
    Eur Urol; 2016 Jan; 69(1):60-9. PubMed ID: 26210894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Robotic and laparoscopic radical cystectomy for bladder cancer: long-term oncologic outcomes.
    Snow-Lisy DC; Campbell SC; Gill IS; Hernandez AV; Fergany A; Kaouk J; Haber GP
    Eur Urol; 2014 Jan; 65(1):193-200. PubMed ID: 24018019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence and location of lymph node metastases in patients undergoing radical cystectomy for clinical non-muscle invasive bladder cancer: results from a prospective lymph node mapping study.
    Bruins HM; Skinner EC; Dorin RP; Ahmadi H; Djaladat H; Miranda G; Cai J; Daneshmand S
    Urol Oncol; 2014 Jan; 32(1):24.e13-9. PubMed ID: 23395238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
    Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
    Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preoperative detection of Vesical Imaging-Reporting and Data System (VI-RADS) score 5 reliably identifies extravesical extension of urothelial carcinoma of the urinary bladder and predicts significant delayed time to cystectomy: time to reconsider the need for primary deep transurethral resection of bladder tumour in cases of locally advanced disease?
    Del Giudice F; Leonardo C; Simone G; Pecoraro M; De Berardinis E; Cipollari S; Flammia S; Bicchetti M; Busetto GM; Chung BI; Gallucci M; Catalano C; Panebianco V
    BJU Int; 2020 Nov; 126(5):610-619. PubMed ID: 32783347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy.
    Lotan Y; Bagrodia A; Passoni N; Rachakonda V; Kapur P; Arriaga Y; Bolenz C; Margulis V; Raj GV; Sagalowsky AI; Shariat SF
    Eur Urol; 2013 Sep; 64(3):465-71. PubMed ID: 23571005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of site-specific metastases and therapeutic roles of surgery for patients with metastatic bladder cancer: a population-based study.
    Dong F; Shen Y; Gao F; Xu T; Wang X; Zhang X; Zhong S; Zhang M; Chen S; Shen Z
    Cancer Manag Res; 2017; 9():611-626. PubMed ID: 29180897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term oncologic outcomes following robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium.
    Raza SJ; Wilson T; Peabody JO; Wiklund P; Scherr DS; Al-Daghmin A; Dibaj S; Khan MS; Dasgupta P; Mottrie A; Menon M; Yuh B; Richstone L; Saar M; Stoeckle M; Hosseini A; Kaouk J; Mohler JL; Rha KH; Wilding G; Guru KA
    Eur Urol; 2015 Oct; 68(4):721-8. PubMed ID: 25985883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preoperative chemotherapy in clinically node positive muscle invasive bladder cancer: Radiologic variables can predict response.
    Ghodoussipour S; Xu W; Tran K; Atkinson R; Cho D; Miranda G; Cai J; Bhanvadia S; Schuckman A; Daneshmand S; Djaladat H
    Urol Oncol; 2021 Feb; 39(2):133.e1-133.e8. PubMed ID: 32900621
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mediator Complex Subunit MED1 Protein Expression Is Decreased during Bladder Cancer Progression.
    Klümper N; Syring I; Vogel W; Schmidt D; Müller SC; Ellinger J; Adler D; Brägelmann J; Perner S
    Front Med (Lausanne); 2017; 4():30. PubMed ID: 28367434
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Lymphadenopathy in Urothelial Cancer: A Transatlantic Collaboration on Performance of Cross-sectional Imaging and Oncologic Outcomes in Patients Treated with Radical Cystectomy Without Neoadjuvant Chemotherapy.
    Moschini M; Morlacco A; Briganti A; Hu B; Colombo R; Montorsi F; Frank I; Daneshmand S; Karnes RJ
    Eur Urol Focus; 2018 Mar; 4(2):245-251. PubMed ID: 28753820
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conditional survival after radical cystectomy for bladder cancer: evidence for a patient changing risk profile over time.
    Ploussard G; Shariat SF; Dragomir A; Kluth LA; Xylinas E; Masson-Lecomte A; Rieken M; Rink M; Matsumoto K; Kikuchi E; Klatte T; Boorjian SA; Lotan Y; Roghmann F; Fairey AS; Fradet Y; Black PC; Rendon R; Izawa J; Kassouf W
    Eur Urol; 2014 Aug; 66(2):361-70. PubMed ID: 24139235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
    Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
    Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
    Słojewski M
    Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathologic nodal staging score for bladder cancer: a decision tool for adjuvant therapy after radical cystectomy.
    Shariat SF; Rink M; Ehdaie B; Xylinas E; Babjuk M; Merseburger AS; Svatek RS; Cha EK; Tagawa ST; Fajkovic H; Novara G; Karakiewicz PI; Trinh QD; Daneshmand S; Lotan Y; Kassouf W; Fritsche HM; Chun FK; Sonpavde G; Joual A; Scherr DS; Gonen M
    Eur Urol; 2013 Feb; 63(2):371-8. PubMed ID: 22727174
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer.
    Kramer MW; Golshani R; Merseburger AS; Knapp J; Garcia A; Hennenlotter J; Duncan RC; Soloway MS; Jorda M; Kuczyk MA; Stenzl A; Lokeshwar VB
    Eur Urol; 2010 Jan; 57(1):86-93. PubMed ID: 19345473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.